GLP-1 Analogues Market worth $471.1 billion by 2032

The report "GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032", is projected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period 

Browse 405 market data Tables and 59 Figures spread through 315 Pages and in-depth TOC on "GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html

The single dose segment is the fastest-growing of the GLP-1 Analogue market by product format  

Based on product format, the global GLP-1 Analogue market is segmented into single-dose, multi-dose, and tablets. In 2023, the single dose segment accounted for the highest growth rate in the GLP-1 Analogue market by product format type. Single dose format is a highly convenient form of the GLP-1 analogs for self-administration as it is increasingly becoming available in the autoinjector form. Additionally, the format is for a lower frequency of administration (majorly once a week). This aids in long term adherence to treatment by patients.

Ozempic (semaglutide) is the largest segment of the GLP-1 Analogues market by product

Based on the products, the global GLP-1 analogues market is segmented into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. In 2023, Ozempic (semaglutide) accounted for the largest share of the product segment of the GLP-1 Analogue market. The large share of this market segment can be attributed to the increasing adoption of Ozempic for the treatment of type-2 diabetes. Additionally, the product revenue reveals stable high growth over the years.

Europe: The second-largest region in the GLP-1 Analogue market.

The European market for GLP-1 analogue drugs is the second-largest market globally. The share of this market can be attributed to several key factors. Some of the factors include the strong presence of key market players offering GLP-1 drugs, favorable regulatory scenario and availability of majority of GLP-1 products in the region with reimbursement offered in several countries.

The market for GLP-1 Analogue class drugs is highly consolidated, with two major players controlling major shares of the market. Prominent players in the market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China) among others.

Don’t miss out on business opportunities in GLP-1 Analogues Market. Speak to our analyst and gain crucial industry insights that will help your business grow.